Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T-cell therapy plus autologous tumor cell vaccination in metastatic melanoma
NL-OMON37167Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2013
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa in melanoma, sponsored by Leiden University Medical Center. Primary endpoints: Feasibility and Safety and toxicity. Started Feb 2013; status: recruiting.
02
Drugs
interferon alfa
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON37167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37167.